JXR (01951) announced that effective August 27, 2025, Dr. John G. Wilcox has resigned from his position as executive director, as well as his memberships on the nomination committee, strategic decision committee, and medical quality control and research development committee, in order to focus on his management role in the group's US operations. On the same date, Dr. Geng Lihong has been appointed as a member of the medical quality control and research development committee.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.